Enliven Therapeutics

NYSE: ELVN ↗ $45.10 USD ~$700M MCAP

#Acute Myeloid Leukemia (AML)#NPM1-Mutant Leukemia #KMT2A-Rearranged Leukemia #Allosteric Inhibitors #Precision Oncology

Enliven Therapeutics is a clinical-stage precision oncology company developing allosteric small-molecule therapies targeting validated oncology pathways, with a focus on menin inhibitors for acute myeloid leukemia (AML) and other genetically defined cancers. Its lead program ELVN-001 is being developed for patients with NPM1-mutant and KMT2A-rearranged leukemias.

Company Info

Sector: Biotechnology / Precision Oncology

Headquarters: Boulder, Colorado, USA

Founded: 2019

Website: www.enliventherapeutics.com/

Upcoming Milestones & Key Dates

Mid 2026

Clinical Trial

ELVN-001 Phase 1 dose-escalation update in AML

Late 2026

Clinical Trial

ELVN-002 initial Phase 1 data in HER2-mutant solid tumors

Clinical Development Pipeline

ELVN-001

Target: Allosteric menin inhibitor

NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ELVN-002

Target: Allosteric HER2 tyrosine kinase inhibitor

HER2-mutant and amplified solid tumors (NSCLC, breast, gastric)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

ELVN-003

Target: Allosteric KIT inhibitor

Gastrointestinal stromal tumors (GIST)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Enliven Therapeutics' Leukemia Drug Shows Promise in New Study ↗

Enliven Therapeutics reported updated clinical data for its allosteric menin inhibitor ELVN-001 in acute myeloid leukemia (AML), showing promising response rates and tolerability in heavily pretreated patients.

Leadership Team

Dr. Sam Kintz

Co-Founder and Chief Executive Officer

Dr. Anish Patel

Chief Medical Officer

Dr. Joseph P. Lyssikatos

Co-Founder and Head of Chemistry

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →